Vertex enters into a definitive agreement to acquire Alpine Immune Sciences
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, yesterday announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and […]
